Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Wei Guang Biological: Received the drug registration clinical trial acceptance notice
Weiguang Biological Announcement: Recently received the “Acceptance Notice” (Acceptance Number: CXSL2600307) from the National Medical Products Administration for the domestic clinical trial application of human coagulation factor IX.
The drug name is human coagulation factor IX, with a specification of 500 IU/bottle, registered as a Class 3.4 therapeutic biological product, used for bleeding treatment in patients with factor IX deficiency (hemophilia B).